4SC 202

Drug Profile

4SC 202

Alternative Names: 4SC-202

Latest Information Update: 17 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nycomed
  • Developer 4SC
  • Class Antineoplastics; Benzamides; Pyrazoles; Pyrroles; Small molecules; Sulfones
  • Mechanism of Action BRD4 protein modulators; HDAC1 protein inhibitors; HDAC2 protein inhibitors; HDAC3 protein inhibitors; Lysine specific demethylase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Malignant melanoma
  • Phase I Haematological malignancies
  • Preclinical Cancer; Pancreatic cancer; Small cell lung cancer

Most Recent Events

  • 25 Sep 2017 Phase-I/II clinical trials in Malignant melanoma (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in Germany (PO) (NCT03278665)
  • 20 Sep 2017 4SC plans the phase II SENSITIZE trial for Malignant melanoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Unresectable/Inoperable) (PO) (NCT03278665)
  • 02 Jun 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the 53rd annual meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top